Tuberculosis (TB) is an infectious disease usually caused by the bacterium Mycobacterium tuberculosis (MTB). Tuberculosis generally affects the lungs, but can also affect other parts of the body. Most infections do not have symptoms, in which case it is known as latent tuberculosis. About 10% of latent infections progress to active disease which, if left untreated, kills about half of those infected. The classic symptoms of active TB are a chronic cough with blood-containing sputum, fever, night sweats, and weight loss.
The increasing number of government and non-government initiatives to eradicate tuberculosis (TB) is expected to be one of the primary drivers for the global tuberculosis (TB) diagnostics market growth till 2023. A global TB control program was introduced by the US Agency for International Development (USAID) in the year 1998. To support the eradication of TB, the US prioritized and provided increased funding for bilateral and multilateral programs in the subsequent decades. Similarly, the division of tuberculosis elimination (DTBE), adopted strategic plans to control TB in the US. These programs reduce the incidence and mortality by 50%.
The increasing prevalence of TB and rising population in APAC is driving the growth prospects for the global tuberculosis (TB) diagnostics market in the region. The governments in the region are motivated to take measures to improve the healthcare infrastructure. They are also extensively focusing on the preventive care due to the rising population, especially in China and India. Furthermore, the enhancement of healthcare infrastructure in countries such as Singapore, Japan, Australia, and South Korea will boost the adoption of tuberculosis diagnostics in the APAC region.
In 2018, the global Tuberculosis (TB) Diagnostics market size was 2040 million US$ and it is expected to reach 2770 million US$ by the end of 2025, with a CAGR of 3.9% during 2019-2025.
This report focuses on the global Tuberculosis (TB) Diagnostics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Tuberculosis (TB) Diagnostics development in United States, Europe and China.
The key players covered in this study
F. Hoffmann-La Roche
Thermo Fisher Scientific
Market segment by Type, the product can be split into
Mantoux Tuberculin Test
Drug Susceptibility Testing
LF-LAM for PLHIV
Market segment by Application, split into
Market segment by Regions/Countries, this report covers
Central & South America
The study objectives of this report are:
To analyze global Tuberculosis (TB) Diagnostics status, future forecast, growth opportunity, key market and key players.
To present the Tuberculosis (TB) Diagnostics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Tuberculosis (TB) Diagnostics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.